EV/EBIT Ratio: 27.17x
Is the EV/EBIT ratio high or low?
The EV/EBIT ratio of 27.17x is 39% above its 5-year average of 19.55x, near the high end of its 5-year range (8.44x–31.32x).
As of Saturday, June 27, 2026. 57.38% above its 12-month average of 17.26x.
NRC EV/EBIT Ratio Chart
NRC Average EV/EBIT Ratio Chart
NRC Current vs Average EV/EBIT Ratio Chart
NRC EV/EBIT Ratio Metrics
EV/EBIT RATIO
27.17x
EV/EBIT RATIO AVG TTM
17.26x
EV/EBIT RATIO AVG 3Y
17.93x
EV/EBIT RATIO AVG 5Y
19.55x
EV/EBIT RATIO AVG 10Y
23.51x
EV/EBIT RATIO AVG 15Y
N/A
EV/EBIT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+57.38%
CURRENT VS 3Y AVG
+51.50%
CURRENT VS 5Y AVG
+38.96%
CURRENT VS 10Y AVG
+15.56%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
NRC Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| National Research Corporation (NRC) | $468.99M | 27.17x | 17.26x | 17.93x | 19.55x |
| Shoulder Innovations, Inc. (SI)vs › | $472.62M | N/A | -15.91x | -20.06x | -20.06x |
| 23andMe Holding Co. (ME)vs › | $15.31M | N/A | -0.28x | -1.89x | -7.82x |
| Teladoc Health, Inc. (TDOC)vs › | $1.51B | N/A | -3.74x | -5.94x | -19.44x |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.21B | 20.10x | 18.81x | 18.81x | 23.55x |
| TransMedics Group, Inc. (TMDX)vs › | $2.37B | 30.48x | 55.61x | 68.11x | 68.11x |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.56B | 268.16x | 104.01x | 149.60x | 149.60x |
| Oscar Health, Inc. (OSCR)vs › | $7.72B | 513.82x | 208.79x | 113.43x | 113.43x |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $8.13B | 37.49x | 38.30x | 32.90x | 33.23x |
| Universal Health Services, Inc. (UHS)vs › | $9.12B | 6.85x | 9.17x | 11.71x | 11.79x |
EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for National Research Corporation (NRC)?
- The EV/EBIT ratio for NRC stock is 27.17x.
- Is National Research Corporation's EV/EBIT ratio high or low?
- The EV/EBIT ratio of 27.17x is 39% above its 5-year average of 19.55x, near the high end of its 5-year range (8.44x–31.32x).
- What is the TTM average EV/EBIT ratio for National Research Corporation (NRC)?
- The TTM average EV/EBIT ratio for NRC stock is 17.26x.
- What is the 3Y average EV/EBIT ratio for National Research Corporation (NRC)?
- The 3Y average EV/EBIT ratio for NRC stock is 17.93x.
- What is the 5Y average EV/EBIT ratio for National Research Corporation (NRC)?
- The 5Y average EV/EBIT ratio for NRC stock is 19.55x.
- What is the 10Y average EV/EBIT ratio for National Research Corporation (NRC)?
- The 10Y average EV/EBIT ratio for NRC stock is 23.51x.
NRC EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-26 | 27.17x |
| 2026-06-25 | 26.87x |
| 2026-06-24 | 27.04x |
| 2026-06-23 | 26.31x |
| 2026-06-22 | 25.69x |
| 2026-06-18 | 24.63x |
| 2026-06-17 | 23.74x |
| 2026-06-16 | 24.55x |
| 2026-06-15 | 24.37x |
| 2026-06-12 | 24.91x |
| 2026-06-11 | 24.91x |
| 2026-06-10 | 27.69x |
| 2026-06-09 | 25.98x |
| 2026-06-08 | 25.51x |
| 2026-06-05 | 25.30x |
| 2026-06-04 | 25.98x |
| 2026-06-03 | 25.19x |
| 2026-06-02 | 25.80x |
| 2026-06-01 | 26.54x |
| 2026-05-29 | 25.73x |
| 2026-05-28 | 25.88x |
| 2026-05-27 | 25.29x |
| 2026-05-26 | 25.19x |
| 2026-05-22 | 25.23x |
| 2026-05-21 | 25.19x |
| 2026-05-20 | 25.43x |
| 2026-05-19 | 24.86x |
| 2026-05-18 | 24.85x |
| 2026-05-15 | 24.71x |
| 2026-05-14 | 25.06x |
| 2026-05-13 | 24.77x |
| 2026-05-12 | 25.35x |
| 2026-05-11 | 24.82x |
| 2026-05-08 | 24.86x |
| 2026-05-07 | 24.84x |
| 2026-05-06 | 23.86x |
| 2026-05-05 | 21.41x |
| 2026-05-04 | 20.90x |
| 2026-05-01 | 20.12x |
| 2026-04-30 | 19.21x |
| 2026-04-29 | 19.28x |
| 2026-04-28 | 19.57x |
| 2026-04-27 | 19.83x |
| 2026-04-24 | 19.95x |
| 2026-04-23 | 19.97x |
| 2026-04-22 | 20.21x |
| 2026-04-21 | 19.90x |
| 2026-04-20 | 20.87x |
| 2026-04-17 | 20.72x |
| 2026-04-16 | 20.33x |
| 2026-04-15 | 20.54x |
| 2026-04-14 | 19.77x |
| 2026-04-13 | 19.55x |
| 2026-04-10 | 19.23x |
| 2026-04-09 | 19.78x |
| 2026-04-08 | 19.98x |
| 2026-04-07 | 19.77x |
| 2026-04-06 | 20.05x |
| 2026-04-02 | 19.88x |
| 2026-04-01 | 20.06x |
| 2026-03-31 | 19.71x |
| 2026-03-30 | 19.86x |
| 2026-03-27 | 19.85x |
| 2026-03-26 | 20.23x |
| 2026-03-25 | 19.90x |
| 2026-03-24 | 20.15x |
| 2026-03-23 | 20.22x |
| 2026-03-20 | 20.04x |
| 2026-03-19 | 20.03x |
| 2026-03-18 | 20.28x |
| 2026-03-17 | 20.43x |
| 2026-03-16 | 20.11x |
| 2026-03-13 | 19.26x |
| 2026-03-12 | 19.24x |
| 2026-03-11 | 18.77x |
| 2026-03-10 | 19.02x |
| 2026-03-09 | 17.77x |
| 2026-03-06 | 17.40x |
| 2026-03-05 | 16.87x |
| 2026-03-04 | 13.60x |
| 2026-03-03 | 13.82x |
| 2026-03-02 | 14.20x |
| 2026-02-27 | 13.84x |
| 2026-02-26 | 13.87x |
| 2026-02-25 | 13.45x |
| 2026-02-24 | 13.09x |
| 2026-02-23 | 13.09x |
| 2026-02-20 | 14.05x |
| 2026-02-19 | 13.05x |
| 2026-02-18 | 12.95x |
| 2026-02-17 | 12.71x |
| 2026-02-13 | 12.75x |
| 2026-02-12 | 13.36x |
| 2026-02-11 | 14.12x |
| 2026-02-10 | 14.79x |
| 2026-02-09 | 15.45x |
| 2026-02-06 | 15.92x |
| 2026-02-05 | 15.91x |
| 2026-02-04 | 15.37x |
| 2026-02-03 | 17.30x |
| 2026-02-02 | 20.81x |
| 2026-01-30 | 19.53x |
| 2026-01-29 | 19.29x |
| 2026-01-28 | 19.10x |
| 2026-01-27 | 19.54x |
| 2026-01-26 | 19.92x |
| 2026-01-23 | 20.13x |
| 2026-01-22 | 20.90x |
| 2026-01-21 | 21.29x |
| 2026-01-20 | 20.80x |
| 2026-01-16 | 21.08x |
| 2026-01-15 | 20.32x |
| 2026-01-14 | 19.94x |
| 2026-01-13 | 19.98x |
| 2026-01-12 | 19.61x |
| 2026-01-09 | 19.02x |
| 2026-01-08 | 18.83x |
| 2026-01-07 | 18.35x |
| 2026-01-06 | 18.68x |
| 2026-01-05 | 18.27x |
| 2026-01-02 | 17.63x |
| 2025-12-31 | 18.24x |
| 2025-12-30 | 18.14x |
| 2025-12-29 | 18.41x |
| 2025-12-26 | 18.15x |
| 2025-12-24 | 18.28x |
| 2025-12-23 | 18.44x |
| 2025-12-22 | 18.33x |
| 2025-12-19 | 18.18x |
| 2025-12-18 | 18.68x |
| 2025-12-17 | 18.14x |
| 2025-12-16 | 17.96x |
| 2025-12-15 | 17.61x |
| 2025-12-12 | 17.31x |
| 2025-12-11 | 17.13x |
| 2025-12-10 | 16.73x |
| 2025-12-09 | 16.00x |
| 2025-12-08 | 15.84x |
| 2025-12-05 | 15.86x |
| 2025-12-04 | 16.23x |
| 2025-12-03 | 16.11x |
| 2025-12-02 | 16.13x |
| 2025-12-01 | 16.62x |
| 2025-11-28 | 16.78x |
| 2025-11-26 | 17.01x |
| 2025-11-25 | 17.63x |
| 2025-11-24 | 17.05x |
| 2025-11-21 | 17.33x |
| 2025-11-20 | 16.47x |
| 2025-11-19 | 16.22x |
| 2025-11-18 | 16.01x |
| 2025-11-17 | 15.98x |
| 2025-11-14 | 15.34x |
| 2025-11-13 | 15.59x |
| 2025-11-12 | 15.50x |
| 2025-11-11 | 15.09x |
| 2025-11-10 | 14.72x |
| 2025-11-07 | 14.90x |
| 2025-11-06 | 14.43x |
| 2025-11-05 | 14.21x |
| 2025-11-04 | 13.98x |
| 2025-11-03 | 13.55x |
| 2025-10-31 | 13.63x |
| 2025-10-30 | 13.42x |
| 2025-10-29 | 13.71x |
| 2025-10-28 | 13.55x |
| 2025-10-27 | 12.05x |
| 2025-10-24 | 12.25x |
| 2025-10-23 | 12.25x |
| 2025-10-22 | 12.44x |
| 2025-10-21 | 12.60x |
| 2025-10-20 | 12.47x |
| 2025-10-17 | 12.21x |
| 2025-10-16 | 12.26x |
| 2025-10-15 | 12.08x |
| 2025-10-14 | 12.13x |
| 2025-10-13 | 12.10x |
| 2025-10-10 | 12.10x |
| 2025-10-09 | 12.30x |
| 2025-10-08 | 12.46x |
| 2025-10-07 | 12.54x |
| 2025-10-06 | 12.58x |
| 2025-10-03 | 12.70x |
| 2025-10-02 | 12.90x |
| 2025-10-01 | 12.93x |
| 2025-09-30 | 13.16x |
| 2025-09-29 | 13.15x |
| 2025-09-26 | 13.59x |
| 2025-09-25 | 14.03x |
| 2025-09-24 | 14.61x |
| 2025-09-23 | 14.70x |
| 2025-09-22 | 15.15x |
| 2025-09-19 | 14.81x |
| 2025-09-18 | 15.70x |
| 2025-09-17 | 15.72x |
| 2025-09-16 | 15.84x |
| 2025-09-15 | 15.95x |
| 2025-09-12 | 15.80x |
| 2025-09-11 | 15.95x |
| 2025-09-10 | 15.70x |
| 2025-09-09 | 15.90x |
| 2025-09-08 | 15.59x |
| 2025-09-05 | 15.30x |
| 2025-09-04 | 14.94x |
| 2025-09-03 | 14.75x |
| 2025-09-02 | 15.03x |
| 2025-08-29 | 14.72x |
| 2025-08-28 | 14.69x |
| 2025-08-27 | 15.37x |
| 2025-08-26 | 15.28x |
| 2025-08-25 | 15.19x |
| 2025-08-22 | 15.28x |
| 2025-08-21 | 14.57x |
| 2025-08-20 | 15.56x |
| 2025-08-19 | 15.93x |
| 2025-08-18 | 15.39x |
| 2025-08-15 | 15.23x |
| 2025-08-14 | 14.97x |
| 2025-08-13 | 15.44x |
| 2025-08-12 | 15.41x |
| 2025-08-11 | 15.05x |
| 2025-08-08 | 15.06x |
| 2025-08-07 | 11.42x |
| 2025-08-06 | 11.08x |
| 2025-08-05 | 10.85x |
| 2025-08-04 | 10.75x |
| 2025-08-01 | 10.04x |
| 2025-07-31 | 9.99x |
| 2025-07-30 | 10.07x |
| 2025-07-29 | 10.49x |
| 2025-07-28 | 10.93x |
| 2025-07-25 | 10.90x |
| 2025-07-24 | 11.05x |
| 2025-07-23 | 11.45x |
| 2025-07-22 | 11.08x |
| 2025-07-21 | 11.00x |
| 2025-07-18 | 11.12x |
| 2025-07-17 | 11.60x |
| 2025-07-16 | 11.60x |
| 2025-07-15 | 11.69x |
| 2025-07-14 | 11.88x |
| 2025-07-11 | 12.26x |
| 2025-07-10 | 12.46x |
| 2025-07-09 | 12.77x |
| 2025-07-08 | 12.85x |
| 2025-07-07 | 12.59x |
| 2025-07-03 | 12.95x |
| 2025-07-02 | 12.64x |
| 2025-07-01 | 12.72x |
| 2025-06-30 | 12.81x |
| 2025-06-27 | 12.72x |
| 2025-06-26 | 12.41x |
| 2025-06-25 | 12.83x |
| 2025-06-24 | 13.10x |
| 2025-06-23 | 12.94x |
| 2025-06-20 | 12.64x |
| 2025-06-18 | 12.83x |
| 2025-06-17 | 12.79x |
| 2025-06-16 | 12.70x |
| 2025-06-13 | 12.31x |
Showing the most recent 260 of 3,293 data points. The chart above shows the full history.
Related Metrics
About National Research Corporation
National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Trent Green